Following a biologics license application (BLA) filled early in 2020, Blenrep® has just been approved by the FDA as well as by the EMA, as a first-in-class anti-BCMA therapy against multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.